Merck & Co, shares trade near Wall Street consensus
Published on 06/27/2026 at 11:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-27, 09:13.
Merck & Co. (US58933Y1055) trades on NASDAQ in New York, with analysts still clustering around a moderate buy call. TradingKey showed MRK at 128.40 dollars at the 06/26 close, while Pricetargets put the consensus target at 128.72 dollars.
Analysts stay close
The latest market snapshot on TradingKey lists a market cap of 317.74 billion dollars and a trailing P/E of 35.99. The same page shows the share price up 2.35 percent at the close on 06/26.
The consensus page at Pricetargets counts 20 analysts for MRK, with 12 Buy ratings, 7 Hold ratings and 0 Sell ratings. That mix leaves the stock in the Moderate Buy bracket.
Wall Street signal
For a US large-cap pharma name, that setup matters because the market is still paying close attention to earnings quality and pipeline visibility. A fresh analyst print from a named consensus source can keep the focus on MRK even on a quiet calendar day.
All news and analysis on Merck & Co. shares
The consensus setup on MRK is centered on Wall Street ratings, market cap and the last close.
The company behind it
Merck & Co.'s core business spans prescription medicines and vaccines, with Keytruda and Gardasil among its best-known products. That portfolio gives the stock a clear link to oncology and immunization revenue.
The listing in brief
The Merck & Co. shares (US58933Y1055) trade on 2026-06-27, 09:13 on NASDAQ at 128.40 dollars.
Key data on Merck & Co. shares
- Company: Merck & Co., Inc.
- ISIN: US58933Y1055
- Ticker: MRK
- Trading venue: NASDAQ
- Price (as of 2026-06-26, 16:00 ET): 128.40 USD
- Market cap: 317.74B USD (as of 2026-06-26)
- Sector / industry: Health Care - Pharmaceuticals
- Index membership: Dow Jones Industrial Average
Disclaimer: This article is for information only and does not constitute investment advice.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
